Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma-Reference-Cited by-同舟云学术

Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma

Published:2023-05 Issue:5 Volume:29 Page:335.e1-335.e8
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Kersten Marie José,Qiao Yao,Shah Ruchit^ORCID,Solem Caitlyn^ORCID,Snider Julia Thornton,To Christina,Cheng Paul,Spooner Clare,Perales Miguel-Angel

Funder

Kite Pharma Inc

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference13 articles.

1. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma;Locke;N Engl J Med,2022

2. Systematic review and benchmarking of quality-adjusted time without symptoms or toxicity (Q-TWiST) in oncology;Solem;Expert Rev Pharmacoecon Outcomes Res,2018

3. European Medicines Agency. Revised framework of EMA interaction with patients, consumers and their organisations. November 26, 2014. Available at:https://www.ema.europa.eu/en/documents/presentation/presentation-revised-framework-european-medicines-agency-interaction-patients-consumers-their_en.pdf. Accessed June 17, 2022.

4. American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options;Schnipper;J Clin Oncol,2015

5. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS);Cherny;Ann Oncol,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States;Journal of Medical Economics;2023-12-19

2. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma;New England Journal of Medicine;2023-07-13